Core Insights - Evolent Health reported revenue of 646.54millionforthequarterendedDecember2024,reflectingayear−over−yearincreaseof16.30.02, a decline from 0.23inthesamequarterlastyear,withnosurpriseagainsttheconsensusEPSestimateof−0.02 [1] Financial Performance Metrics - Evolent Health's shares have returned +5.2% over the past month, outperforming the Zacks S&P 500 composite's +2.6% change, and currently holds a Zacks Rank 3 (Hold) [3] - Average PMPM Fees / Revenue per Case for the Performance Suite was 21.32,slightlybelowtheestimated21.81 [4] - Average PMPM Fees / Revenue per Case for the Specialty Technology and Services Suite matched the estimate at 0.37[4]−AveragePMPMFees/RevenueperCaseforAdministrativeServiceswas16.43, exceeding the estimate of 15.44[4]−AverageLivesonPlatformforCaseswas16thousand,surpassingtheestimateof14.27thousand[4]−AverageLivesonPlatformforthePerformanceSuitewas7.15million,slightlybelowtheestimateof7.19million[4]−AverageLivesonPlatformfortheSpecialtyTechnologyandServicesSuitewas75.16million,comparedtotheestimateof75.59million[4]−AverageLivesonPlatformforAdministrativeServiceswas1.2million,belowtheestimateof1.27million[4]−AveragePMPMFees/RevenueperCaseforCaseswas3,073, exceeding the average estimate of $2,976.69 [4]